Zytorvi 240mg Injection

Salt Composition: Toripalimab

Manufacturer: DR REDDY'S LABORATORIES LTD

0 0 13

Status

Out of Stock

Zytorvi 240mg Injection contains Toripalimab, a monoclonal antibody used to treat metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC). It is prescribed as a first-line treatment in combination with cisplatin and gemcitabine for adult patients or as a monotherapy for individuals with recurrent, unresectable, or metastatic NPC that has progressed following platinum-based chemotherapy.

This injection works by targeting and blocking the PD-1 receptor, which prevents its interaction with the PD-L1 and PD-L2 ligands. By disrupting this pathway, the treatment removes the suppression on T-cell activity, thereby enhancing immune surveillance and promoting a stronger anti-tumor immune response. In preclinical studies, blocking PD-1 led to reduced tumor growth.

Common side effects of Zytorvi 240mg Injection include nausea, vomiting, loss of appetite, diarrhea, constipation, and tingling or burning sensations in the feet and toes. It may also cause severe immune-mediated side effects affecting various organs or tissues, which can be life-threatening. These reactions may appear at any point during or after treatment, necessitating close monitoring and immediate medical attention if symptoms arise.

Infusion-related reactions such as hypersensitivity or anaphylaxis may occur during administration. In patients who have received or are receiving allogeneic hematopoietic stem cell transplantation (HSCT), this medicine can lead to serious complications, including graft-versus-host disease (GVHD) and other transplant-related issues. Zytorvi 240mg Injection is contraindicated during pregnancy due to the potential risk of fetal harm or fetal death.

Uses